Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2022 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The question asks about unit size escalation, not just volume. Looking at the transcript, management discusses various business lines. Key points: They mention growth in volumes, but do they mention that individual deals, contracts, or engagements are larger? For example, in the context of SOFR, they talk about adoption rates, but not about size of individual contracts. In the context of international growth, they talk about new customers and cross-selling, but not about larger individual engagements. They mention the investment in S&P Dow Jones Indices JV, but that's a one-time investment, not a recurring business engagement. They talk about the Google partnership, but that's a strategic partnership, not a repeatable business unit. They mention the launch of new products, but not that each new product is larger. The question specifically asks about "successive engagements of the same kind" — meaning the same offering being sold in larger units over time. There is no mention of that. Management talks about record volumes, but that's more units, not larger unit size. They also talk about fee waivers and incentives, but that's about pricing, not size. They mention that SOFR futures ADV is 134% of Eurodollar, but that's about volume share, not individual contract size. No mention of larger orders, larger contracts, larger projects. The only thing close is the investment in the JV, but that's a one-time capital investment, not a recurring business engagement. Also, they mention that the joint venture earnings have tripled, but that's over years, not a recent escalation in unit size. The question requires a comparison against the company's own recent past for the same offering, and that the escalation is early and expected to continue. None of that is present. So answer NO. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.